LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety

By LabMedica International staff writers
Posted on 27 Mar 2024
Print article
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)
Image: The cobas Malaria test is the first FDA-approved molecular test to screen U.S. blood donors for malaria (Photo courtesy of Roche)

Malaria, a serious illness that often leads to death, is spread by a specific mosquito species that infect humans with a parasite. Other transmission modes include blood transfusions, organ transplants, and shared needles or syringes contaminated with infected blood. Although the largest burden of malaria is in sub-Saharan Africa, Southeast Asia, the Eastern Mediterranean, the Western Pacific, and the Americas also report many cases and deaths. Because of the risk of malaria transmission, many potential blood donors who have traveled to or lived in malaria-endemic areas are currently ineligible to donate blood. The existing methods for detecting malaria in blood, such as microscopy and serology, lack the necessary sensitivity to ensure the safety of blood transfusions. Now, the first FDA-approved molecular test to screen U.S. blood donors for malaria marks a significant advancement in maintaining a safe global blood supply.

Roche (Basel, Switzerland) has obtained FDA approval for the cobas Malaria test for use on the cobas 6800/8800 Systems. This test enables healthcare providers to minimize the risks of malaria transmission through blood transfusion by identifying blood units infected with malaria. It screens for the five primary species of Plasmodium parasites that cause malaria in humans, enhancing both the safety and availability of blood supplies. Designed for screening blood, organs, and tissue donations, the cobas Malaria test is a qualitative in vitro test that detects Plasmodium RNA and DNA in whole blood samples from individual donors. It is essential to note that the test is not for diagnosing Plasmodium infections, nor is it applicable to cord blood samples or cadaveric blood specimens. Utilizing the Roche Whole Blood Collection Tube, the test streamlines the workflow by allowing direct blood draws from donors and immediate processing on the cobas 6800/8800 Systems.

“As the first FDA-approved blood screening test for malaria, this represents an important step forward in safeguarding the global supply of donated blood," said Matt Sause, CEO of Roche Diagnostics. “The approval of cobas Malaria represents a significant advancement in malaria detection, offering healthcare professionals a reliable tool for donor screening and improving the safety of patients worldwide.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Plasma Control
Plasma Control Level 1

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more